Literature DB >> 32105090

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.

Eakachai Prompetchara1,1,2, Chutitorn Ketloy1,1, Tanapat Palaga3,4.   

Abstract

As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to provide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in the near future.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32105090     DOI: 10.12932/AP-200220-0772

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  518 in total

1.  Foundation and Clinical Evaluation of a New Method for Detecting SARS-CoV-2 Antigen by Fluorescent Microsphere Immunochromatography.

Authors:  Chunyan Zhang; Lei Zhou; Kang Du; Ying Zhang; Jing Wang; Lijuan Chen; Yanning Lyu; Jun Li; Hao Liu; Junli Huo; Fei Li; Jiayi Wang; Peipei Sang; Si Lin; Yi Xiao; Kan Zhang; Kunlun He
Journal:  Front Cell Infect Microbiol       Date:  2020-11-30       Impact factor: 5.293

Review 2.  Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.

Authors:  Judy Chen; William J Kelley; Daniel R Goldstein
Journal:  J Immunol       Date:  2020-06-03       Impact factor: 5.422

Review 3.  COVID-19 as an Acute Inflammatory Disease.

Authors:  Rose H Manjili; Melika Zarei; Mehran Habibi; Masoud H Manjili
Journal:  J Immunol       Date:  2020-05-18       Impact factor: 5.422

Review 4.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

5.  Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.

Authors:  Rachel M Golonka; Piu Saha; Beng San Yeoh; Saurabh Chattopadhyay; Andrew T Gewirtz; Bina Joe; Matam Vijay-Kumar
Journal:  Physiol Genomics       Date:  2020-04-10       Impact factor: 3.107

6.  COVID-19: The Need for Immunoprevention at Industrial Scale.

Authors:  Scott B Halstead
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

7.  B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran.

Authors:  Farinaz Safavi; Bardia Nourbakhsh; Amir Reza Azimi
Journal:  Mult Scler Relat Disord       Date:  2020-05-13       Impact factor: 4.339

8.  COVID-19 in children: Current status.

Authors:  Mei-Jy Jeng
Journal:  J Chin Med Assoc       Date:  2020-04-15       Impact factor: 2.743

9.  Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex.

Authors:  Aaron C Petrey; Fares Qeadan; Elizabeth A Middleton; Irina V Pinchuk; Robert A Campbell; Ellen J Beswick
Journal:  J Leukoc Biol       Date:  2020-09-15       Impact factor: 4.962

10.  Looking ahead: The risk of neurologic complications due to COVID-19.

Authors:  Carlos A Pérez
Journal:  Neurol Clin Pract       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.